STAAR Surgical Company $STAA Shares Bought by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. boosted its stake in shares of STAAR Surgical Company (NASDAQ:STAA) by 11.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,421,836 shares of the medical instruments supplier’s stock after acquiring an additional 252,218 shares during the period. Resona Asset Management Co. Ltd. owned about 4.89% of STAAR Surgical worth $40,746,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. CWM LLC raised its position in STAAR Surgical by 74.1% during the second quarter. CWM LLC now owns 1,563 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 665 shares during the period. US Bancorp DE raised its position in shares of STAAR Surgical by 1,693.0% in the first quarter. US Bancorp DE now owns 2,044 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 1,930 shares during the last quarter. Brooklyn Investment Group raised its position in shares of STAAR Surgical by 1,564.0% in the first quarter. Brooklyn Investment Group now owns 2,679 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 2,518 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of STAAR Surgical in the first quarter valued at about $189,000. Finally, Strs Ohio acquired a new stake in shares of STAAR Surgical in the first quarter valued at about $190,000. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Trading Down 0.1%

STAAR Surgical stock opened at $25.25 on Thursday. STAAR Surgical Company has a 12-month low of $13.50 and a 12-month high of $32.00. The stock has a market cap of $1.25 billion, a P/E ratio of -13.08 and a beta of 0.82. The company has a 50-day moving average price of $26.79 and a 200 day moving average price of $22.16.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, November 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.50. STAAR Surgical had a negative net margin of 42.45% and a negative return on equity of 16.11%. The firm had revenue of $94.73 million during the quarter, compared to analysts’ expectations of $92.15 million. During the same period last year, the business earned $0.20 earnings per share. As a group, analysts forecast that STAAR Surgical Company will post -1.14 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on STAA. Canaccord Genuity Group reiterated a “hold” rating and issued a $28.00 target price on shares of STAAR Surgical in a research report on Tuesday, October 21st. Weiss Ratings reiterated a “sell (d)” rating on shares of STAAR Surgical in a research report on Wednesday, October 8th. Stifel Nicolaus set a $28.00 target price on shares of STAAR Surgical and gave the company a “hold” rating in a research report on Thursday, August 7th. Piper Sandler reiterated a “neutral” rating on shares of STAAR Surgical in a research report on Monday, October 27th. Finally, Mizuho increased their target price on shares of STAAR Surgical from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Ten research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, STAAR Surgical has a consensus rating of “Reduce” and an average price target of $20.67.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.